Genetic association in <i>CYP3A4</i> and <i>CYP3A5</i> genes elevate the risk of prostate cancer
Creators: name: Bellah, Sm Faysal
name: Salam, Md. Abdus
name: Billah, S. M. Saker
name: Karim, Md Rezaul
Publisher: name: Taylor & Francis
Year: 2023
Subjects: subject: Medicine
subject: Microbiology
subject: FOS: Biological sciences
subject: Cell Biology
subject: Genetics
subject: Molecular Biology
subject: Physiology
subject: Biotechnology
subject: Evolutionary Biology
subject: Biological Sciences not elsewhere classified
subject: Cancer
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Plant Biology
subject: Virology

description: <i>CYP3A4</i> and <i>CYP3A5</i> are biologically potential genes responsible for prostate cancer. We aimed to analyse the expression and association of <i>CYP3A4</i> and <i>CYP3A5</i> genes in prostate cancer. Web-based bioinformatics tools were used to assess the association of <i>CYP3A4</i> and <i>CYP3A5</i> genes with prostate cancer risks. A case-control study of 210 prostate cancer cases and 207 controls was also approved to determine the allelic variants of the <i>CYP3A4</i> gene- rs2740574 (<i>CYP3A4*1B</i>) and the variant of <i>CYP3A5</i> gene-rs776746 (<i>CYP3A5*3</i>) using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP). The risk of prostate cancer was estimated as odds ratio (OR) and 95% confidence interval (CI) using unrestricted logistic regression models. Our <i>in silico</i> data confirmed that both <i>CYP3A4</i> and <i>CYP3A5</i> genes are significantly associated with higher prostate cancer risks. In the case of <i>CYP3A4*1B</i> polymorphism, the heterozygote (*1 A/*1B), mutant (*1B/*1B), and combined heterozygote plus mutant (*1A/*1B+*1B/*1B) genotypes showed 3.52-fold, 3.90-fold, and 3.67-fold increased risk of prostate cancer, respectively. In the case of <i>CYP3A5*3</i> polymorphism, the heterozygote (*1/*3), mutant (*3/*3), and combined (*1/*3+*3/*3) genotypes were found to be significantly associated with 5.11-, 5.49-, and 5.28-fold greater risk of prostate cancer, respectively. Our results indicate that <i>CYP3A4*1B</i> and <i>CYP3A5*3</i> are significantly associated with increased prostate cancer risk. KEY MESSAGESBioinformatics tools were used and concluded that the <i>CYP3A4</i> and <i>CYP3A5</i> genes were significantly associated with the development and progression of prostate cancer.<i>CYP3A4</i> and <i>CYP3A5</i> polymorphisms were significantly associated with an increased risk of prostate cancer.Polymerase Chain Reaction (PCR)–Restriction Fragment Length Polymorphism (RFLP) was used to estimate polymorphisms of prostate cancer progression in the Bangladeshi population. Bioinformatics tools were used and concluded that the <i>CYP3A4</i> and <i>CYP3A5</i> genes were significantly associated with the development and progression of prostate cancer. <i>CYP3A4</i> and <i>CYP3A5</i> polymorphisms were significantly associated with an increased risk of prostate cancer. Polymerase Chain Reaction (PCR)–Restriction Fragment Length Polymorphism (RFLP) was used to estimate polymorphisms of prostate cancer progression in the Bangladeshi population.